If you have been reading about immunomodulation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
During the Napoleonic Wars, the United States, Sweden, and Sicily fought against the Barbary pirates in the Mediterranean. The Barbary wars were a conflict between the United States and the North African States (Tripoli, Algiers, Tunis, and Morocco).
== Function == The protein encoded by this gene belongs to the basic helix-loop-helix family of transcription factors. This gene product is one of two closely related family members, the HAND proteins are expressed within the developing ventricular chambers, cardiac neural crest, endocardium (HAND2 only) and epicardium (HAND2 only). HAND1 is expressed with myocardium of the primary heart field and plays an essential but poorly understood role in cardiac morphogenesis. HAND1 works jointly with HAND2 in cardiac development of embryos based on a crucial HAND gene dosage system. If HAND1 is over or under expressed then morphological abnormalities can form; most notable are cleft lips and palates. Expression was modeled with a knock-in of phosphorylation to turn on and off gene expression which induced the craniofacial abnormalities. Knock-out experimentation on mice caused death and severe cardiac malformations such as failed cardiac looping, impaired ventricular development and defective chamber septation. This aids in the implication that HAND1 expression is a factor to patients with congenital heart disease. However, a lack of HAND1 in the distal regions of the Neural Crest has no effect on cranial feature formation. Mutation of HAND1 has been shown to hinder the effect of GATA4, another vital cardiac transcription factor, and is associated with congenital heart disease.
When the EWS detects a new drug, the substance will be reported to EMCDDA along with any analytical data such as structures, analysts or components found pertaining to that particular drug. Then, an interconnected system is established to closely monitor the development of the substance. If harm is induced, an initial report is drafted to document the adverse effects of the drug.
Sources: en.wikipedia.org
Ronke Mojoyinola Olabisi (born 26 June 1976) is an associate professor of biomedical engineering at University of California, Irvine. She works on speciality of bone and human tissue. She is working with Mae Jemison on 100 Year Starship, an interdisciplinary initiative that is exploring the possibility of human interstellar travel.
== Synthesis == PEEK polymers are obtained by step-growth polymerization by the dialkylation of bisphenolate salts. Typical is the reaction of 4,4'-difluorobenzophenone with the disodium salt of hydroquinone, which is generated in situ by deprotonation with sodium carbonate. The reaction is conducted around 300 °C in polar aprotic solvents - such as diphenyl sulfone.
Stupor: absence of psycho-motor activity; not actively relating to the environment Catalepsy: passive induction of a posture held against gravity Waxy flexibility: maintaining positions imposed by the examiner Mutism: minimal or absent verbal response (not due to aphasia) Negativism: resistance or lack of response to instructions or external stimuli Posturing: spontaneous and active maintenance of a posture against gravity Mannerisms: odd or exaggerated caricatures of normal actions Stereotypy: repetitive, abnormally frequent, non-goal-directed movements Agitation: excessive activity not influenced by external stimuli Grimacing: sustained facial expression Echolalia: mimicking another's speech Echopraxia: mimicking another's movements Other disorders (additional code 293.89 [F06.1] to indicate the presence of the co-morbid catatonia):
==== Conceptual history ==== In the two-part episodes "Colony" and "End Game", Chris Carter and Frank Spotnitz along with some help from David Duchovny created what would become a recurring character named the Alien Bounty Hunter. According to Carter, Duchovny came to him and said "wouldn't it be great if we had like an alien bounty hunter?" Carter was positive towards the idea and acted upon it. The actor Brian Thompson auditioned for the role in a casting session, where he was competing with another actor. Spotnitz and Carter did not have much time to cast this character, but they knew this casting would be important since they intended the character to become a recurring character. Thompson was chosen according to Spotnitz because he had a very "distinctive look" about him, most notably his face and mouth. After casting him, they told Thompson's agent that he needed a hair cut, because he was originally envisioned as a U.S. Air Force pilot who'd been shot down. When Thompson came to Vancouver, British Columbia, Canada there had been some "misunderstanding" between them, and he had not been told of the hair cut. So the hairstyle seen in this and every episode since was a "compromise" between Thompson and the producers.
Sources: en.wikipedia.org
== Overview == The process of translation starts with the information stored in the nucleotide sequence of DNA. This is first transformed into mRNA, then tRNA specifies which three-nucleotide codon from the genetic code corresponds to which amino acid. Each mRNA codon is recognized by a particular type of tRNA, which docks to it along a three-nucleotide anticodon, and together they form three complementary base pairs. On the other end of the tRNA is a covalent attachment to the amino acid corresponding to the anticodon sequence, with each type of tRNA attaching to a specific amino acid. Because the genetic code contains multiple codons that specify the same amino acid, there are several tRNA molecules bearing different anticodons which carry the same amino acid. The covalent attachment to the tRNA 3' end is catalysed by enzymes called aminoacyl tRNA synthetases. During protein synthesis, tRNAs with attached amino acids are delivered to the ribosome by proteins called elongation factors, which aid in association of the tRNA with the ribosome, synthesis of the new polypeptide, and translocation (movement) of the ribosome along the mRNA. If the tRNA's anticodon matches the mRNA, another tRNA already bound to the ribosome transfers the growing polypeptide chain from its 3' end to the amino acid attached to the 3' end of the newly delivered tRNA, a reaction catalyzed by the ribosome. A large number of the individual nucleotides in a tRNA molecule may be chemically modified, often by methylation or deamidation.
== Adverse effects == As with other drugs that inhibit the renin–angiotensin system, if candesartan is taken by pregnant women during the second or third trimester, it can cause injury and in some cases, death of the developing fetus. Symptomatic hypotension may occur in people who take candesartan and are volume-depleted or salt-depleted, as can also occur when diuretics are coadministered. Reduction in renal glomerular filtration rate may occur; people with renal artery stenosis may be at higher risk. Hyperkalemia may occur; people who are also taking spironolactone or eplerenone may be at higher risk. Anemia may occur, due to inhibition of the renin–angiotensin system. As with other angiotensin receptor blockers, candesartan can rarely cause severe liver injury.
=== Other uses === Dihydroergocryptine can also be used in migraine prophylaxis, as well as for the treatment of low blood pressure in elderly patients and peripheral vascular disorder. More commonly, it is used in combination with two similar compounds, dihydroergocornine and dihydroergocristine. This mixture is called ergoloid or codergocrine.
=== Effect on catecholamine biosynthesis === AMPT inhibits catecholamine biosynthesis at the first step—the hydroxylation of tyrosine. Reduction in catecholamines and their metabolites (normetanephrine, metanephrine, and 4-hydroxy-3-methoxymandelic acid) result from the inhibition of tyrosine using AMPT. AMPT doses of 600 to 4,000 mg per day cause a 20 to 79 percent reduction in total catecholamines in Pheochromocytoma patients. Increase in dosage increases the magnitude of catecholamine synthesis inhibition. This increasing inhibitory effect is seen in dosages up to 1500 mg per day; at higher doses, the inhibitory effect of AMPT decreases. The maximum effect of orally administered AMPT occurs 48 to 72 hours after administration of the drug. Catecholamine production levels return to normal 72 to 96 hours after administration of the drug ceases. Dosages as low as 300 mg per day have been found to have an effect on catecholamine production, which can be measured through urinary excretion analysis and cerebral spinal fluid assays. AMPT is successful at inhibiting catecholamine production in humans whether the rate of synthesis is high, as in pheochromocytoma, or normal as in patients with hypertension.
Late in the game, Freeman obtains a "long jump module" for the HEV suit, allowing him to increase the horizontal distance and speed of his jumps by crouching before jumping. The ability becomes particularly important in the Xen chapters, which introduce platforming-oriented challenges and low-gravity environments that require more precise movement. The Xen sections were subsequently criticized by some reviewers for their emphasis on jumping puzzles and less precise movement compared with the earlier portions of the game. The game also includes online multiplayer in individual and team-based deathmatch modes. Multiplayer uses the game's weapons and environments for competitive matches, providing an alternative to the single-player campaign's scripted progression. Contemporary coverage praised the multiplayer's weapon balance and level design, although its pace differed from faster contemporary shooters such as Quake. The combination of combat, puzzles, environmental interaction, and continuous scripted storytelling contributed to the game's reputation for immersion and interactivity. Contemporary reviewers repeatedly identified these qualities as major departures from the conventions of earlier first-person shooters, with GameSpot describing the game as a major step forward for the genre and other reviewers emphasizing its immersive presentation.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.